Evidence map›Paper›PMID 34642395›Full record

ArticleScientific reports2021

HLA-E circulating and genetic determinants in schizophrenia and bipolar disorder.

Wahid Boukouaci, Mohamed Lajnef, Jean-Romain Richard, Ching-Lien Wu, Jihène Bouassida, Ismail Rafik, Marianne Foiselle, Céline Straczek, Esma Mezouad, Soumia Naamoune and 7 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 1 country.

Wahid BoukouaciINSERM, IMRB, Translational Neuropsychiatry, AP-HP, DMU IMPACT, Fédération Hospitalo-Universitaire de Médecine de Précision en Psychiatrie (FHU ADAPT), Univ Paris Est Créteil, Fondation FondaMental, 94010, Créteil, France.
Mohamed LajnefINSERM, IMRB, Translational Neuropsychiatry, AP-HP, DMU IMPACT, Fédération Hospitalo-Universitaire de Médecine de Précision en Psychiatrie (FHU ADAPT), Univ Paris Est Créteil, Fondation FondaMental, 94010, Créteil, France.
Jean-Romain RichardINSERM, IMRB, Translational Neuropsychiatry, AP-HP, DMU IMPACT, Fédération Hospitalo-Universitaire de Médecine de Précision en Psychiatrie (FHU ADAPT), Univ Paris Est Créteil, Fondation FondaMental, 94010, Créteil, France.
Ching-Lien WuINSERM, IMRB, Translational Neuropsychiatry, AP-HP, DMU IMPACT, Fédération Hospitalo-Universitaire de Médecine de Précision en Psychiatrie (FHU ADAPT), Univ Paris Est Créteil, Fondation FondaMental, 94010, Créteil, France.
Jihène BouassidaINSERM, IMRB, Translational Neuropsychiatry, AP-HP, DMU IMPACT, Fédération Hospitalo-Universitaire de Médecine de Précision en Psychiatrie (FHU ADAPT), Univ Paris Est Créteil, Fondation FondaMental, 94010, Créteil, France.
Ismail RafikINSERM, IMRB, Translational Neuropsychiatry, AP-HP, DMU IMPACT, Fédération Hospitalo-Universitaire de Médecine de Précision en Psychiatrie (FHU ADAPT), Univ Paris Est Créteil, Fondation FondaMental, 94010, Créteil, France.
Marianne FoiselleINSERM, IMRB, Translational Neuropsychiatry, AP-HP, DMU IMPACT, Fédération Hospitalo-Universitaire de Médecine de Précision en Psychiatrie (FHU ADAPT), Univ Paris Est Créteil, Fondation FondaMental, 94010, Créteil, France.
Céline StraczekPharmacie Hospitalière, HU Henri Mondor, 94010, Créteil, France.
Esma MezouadINSERM, IMRB, Translational Neuropsychiatry, AP-HP, DMU IMPACT, Fédération Hospitalo-Universitaire de Médecine de Précision en Psychiatrie (FHU ADAPT), Univ Paris Est Créteil, Fondation FondaMental, 94010, Créteil, France.
Soumia NaamouneINSERM, IMRB, Translational Neuropsychiatry, AP-HP, DMU IMPACT, Fédération Hospitalo-Universitaire de Médecine de Précision en Psychiatrie (FHU ADAPT), Univ Paris Est Créteil, Fondation FondaMental, 94010, Créteil, France.
Sofiane SalahINSERM, IMRB, Translational Neuropsychiatry, AP-HP, DMU IMPACT, Fédération Hospitalo-Universitaire de Médecine de Précision en Psychiatrie (FHU ADAPT), Univ Paris Est Créteil, Fondation FondaMental, 94010, Créteil, France.
Mohamed Amin BencharifINSERM, IMRB, Translational Neuropsychiatry, AP-HP, DMU IMPACT, Fédération Hospitalo-Universitaire de Médecine de Précision en Psychiatrie (FHU ADAPT), Univ Paris Est Créteil, Fondation FondaMental, 94010, Créteil, France.
Arij Ben ChaabenINSERM, IMRB, Translational Neuropsychiatry, AP-HP, DMU IMPACT, Fédération Hospitalo-Universitaire de Médecine de Précision en Psychiatrie (FHU ADAPT), Univ Paris Est Créteil, Fondation FondaMental, 94010, Créteil, France.
Caroline BarauPlateforme de Ressources Biologiques, AP-HP, HU Henri Mondor, 94010, Créteil, France.
Philippe Le CorvoisierInserm, Centre d'Investigation Clinique 1430 et AP-HP, Hôpitaux Universitaires Henri Mondor, Univ Paris Est Creteil, 94010, Créteil, France.
Marion LeboyerINSERM, IMRB, Translational Neuropsychiatry, AP-HP, DMU IMPACT, Fédération Hospitalo-Universitaire de Médecine de Précision en Psychiatrie (FHU ADAPT), Univ Paris Est Créteil, Fondation FondaMental, 94010, Créteil, France.
Ryad TamouzaINSERM, IMRB, Translational Neuropsychiatry, AP-HP, DMU IMPACT, Fédération Hospitalo-Universitaire de Médecine de Précision en Psychiatrie (FHU ADAPT), Univ Paris Est Créteil, Fondation FondaMental, 94010, Créteil, France. tamouza.ryad@gmail.com.
Assistance Publique – Hôpitaux de Paris · FRFédération Hospitalo-Universitaire, Paris Center for Microbiome Medicine · FRFondation FondaMental · FRInstitut Mondor de Recherche Biomédicale · FRUniversité Paris-Est Créteil · FRHôpital Albert-Chenevier · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Schizophrenia (SZ) and bipolar disorders (BD) are severe mental illnesses that lack reliable biomarkers to guide diagnosis and management. As immune dysregulation is associated with these disorders, we utilized the immunoregulatory functions of the natural killer cell inhibitory HLA-E locus to investigate the relationships between HLA-E genetic and expression diversities with SZ and BD risk and severity. Four hundred and forty-four patients meeting DSM-IV criteria for SZ (N = 161) or BD (N = 283) were compared to 160 heathy controls (HC). Circulating levels of the soluble isoform of HLA-E molecules (sHLA-E) were measured and HLA-E*01:01 and HLA-E*01:03 variants genotyped in the whole sample. sHLA-E circulating levels were significantly higher in both SZ and in BD patients compared to HC (pc < 0.0001 and pc = 0.0007 for SZ and BD, respectively). High sHLA-E levels were also observed in stable SZ patients and in acute BD patients experiencing depressive episodes when comparisons were made between the acute and stable subgroups of each disorder. sHLA-E levels linearly increased along HLA-E genotypes (p = 0.0036). In conclusion, HLA-E variants and level may have utility as diagnostic biomarkers of SZ and BD. The possible roles of HLA diversity in SZ and BD etiology and pathophysiology are discussed.

Indexed as

Up-RegulationBiomarkersBipolar DisorderCase-Control StudiesGenetic VariationGenotypeHistocompatibility Antigens Class IHLA-E AntigensHumansMalePatient AcuitySchizophreniaBiomarkersHistocompatibility Antigens Class IHLA-E Antigens

Identifiers

PMID34642395
PMCPMC8511156
OpenAlexW3206511482

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.